THE IMPACT OF HYPERTENSION AND ANTIHIPERTENSIVE TREATMENTS ON PATIENTS WITH SARS-COV-2: A RETROSPECTIVE-COHORT STUDY
Journal of Hypertension
; 40:e29, 2022.
Article
in English
| EMBASE | ID: covidwho-1937691
ABSTRACT
Objective:
Hypertension is one of the most important factors for cardiovascular disease. It has been repeatedly proposed as a prognostic factor of severe COVID- 19 and has been included in clinical risk scores to predict the occurrence of critical illness in ospitalised with COVID-19. Also, it has been postulated the relation between antihypertensive drugs and the severity of COVID-19. The aims of our study were to analyze whether hypertension and antihypertensive treatment represent an independent risk factor for death or intensive care unit admission in patients with SARS-COV2. Design andmethod:
Observational, retrospective, single-center cohort study of all patients admitted to Hospital Virgen Macarena diagnosed with COVID-19 between the months of March and December 2020. A bivariate analysis was performed using Pearson's chi-squareResults:
608 patients required admission for COVID-19. A total of 83.7% were hypertensive, specifically 75.9% were under antihypertensive treatment (35.7% with only 1 drug, 29.9% were taking two drugs, 9% with three drugs, and 1.3% with 4 drugs). 26.2% were treated with an ACEI, 24.8% with ARA-II, 16.8% with calcium-antagonists, 30.9% with diuretics, 21.2% with beta-blockers, 0, 5% with alpha-blockers). Hypertension did not show a statistically significant relationship with mortality (p = 0.34), increase in mortality and ICU admissions. Neither treatment with ACEI (p = 0.4), ARB-II (p = 0.45), calcium antagonists (p = 0.53), diuretics (p = 0.68), alpha blockers (p = 0.07) demonstrated relation with those items. Surprisingly, beta-blockers increased the mortality in patients with SARS-COV2 (p = 0.048). Probably this results can be explained as these drugs were indicated for rate control in patients with atrial fibrillation (p = 0.006). The number of antihypertensive drugs used also did not show a statistically significant relationship with an increase in mortality (p = 0.978).Conclusions:
Hypertension is a highly prevalent pathology in patients ospitalised with COVID-19 infection. However, high blood pressure was not associated with a higher risk for mortality in patients with SARS-COV-2, neither the type or the number of antihypertensive drug used. Only beta-blockers alter outcomes in hypertensive patients with COVID-19, as they were associated with more deaths.
alpha adrenergic receptor blocking agent; antihypertensive agent; beta adrenergic receptor blocking agent; calcium antagonist; diuretic agent; adult; antihypertensive therapy; atrial fibrillation; bivariate analysis; cohort analysis; conference abstract; controlled study; coronavirus disease 2019; female; human; hypertension; hypertensive patient; intensive care unit; major clinical study; male; mortality; nonhuman; retrospective study; risk assessment; risk factor; Severe acute respiratory syndrome coronavirus 2
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
Language:
English
Journal:
Journal of Hypertension
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS